Here are six key notes:
1. The shares were sold at an average price of $48.10, for a total transaction of $721,500.
2. Following the transaction, Mr. Miles directly owns 47,627 shares in the company, valued at $2.29 million.
3. NuVasive has a consensus rating of “buy” and an average target price of $56.56.
4. The stock’s 50-day moving average is $52.28 and its 200-day moving average is $49.03.
5 NuVasive has a 12-month low of $33.33 and a 12-month high of $56.61.
6. The company has a market capitalization of $2.57 billion.
More articles on devices:
SpineGuard sells 1k units in Q3 in the United States: 5 key notes
Hackensack University Medical Center buys spine surgery robot: 4 key notes
Montana board grants Bacterin $100k: 5 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
